Evidence map›Paper›PMID 27798786›Full record

ArticleMolecular imaging and biology2017

Response Monitoring with [

Sandra Heskamp, Linda Heijmen, Danny Gerrits, Janneke D M Molkenboer-Kuenen, Edwin G W Ter Voert, Kathrin Heinzmann, Davina J Honess, Donna-Michelle Smith, John R Griffiths, Sabrina Doblas and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Sandra HeskampDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. sandra.heskamp@radboudumc.nl.ORCID 0000-0001-7250-0846
Linda HeijmenDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Danny GerritsDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Janneke D M Molkenboer-KuenenDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Edwin G W Ter VoertDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Kathrin HeinzmannCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Davina J HonessCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Donna-Michelle SmithCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
John R GriffithsCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Sabrina DoblasLBI, CRI - UMR 1149 Inserm, Université Paris Diderot, Paris, France.
Ralph SinkusBHF Centre of Excellence, Division of Imaging Sciences and Biomedical Engineering, King's College London, King's Health Partners, St. Thomas' Hospital, London, SE1 7EH, UK.
Peter LavermanDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Wim J G OyenDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Arend HeerschapDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Otto C BoermanDepartment of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Radboud University Nijmegen · NLUniversity of Cambridge · GBInserm · FRSt Thomas' Hospital · GB

Funding

Cancer Research UK 11562
6 · The paper itself

Abstract

purposeThe aim of the study was to investigate the potential of diffusion-weighted magnetic resonance imaging (DW-MRI) and 3'-dexoy-3'-[ PROCEDURES: Wag/Rij rats with intrahepatic syngeneic CC531 tumors were treated with 5-FU (15, 30, or 60 mg/kg in weekly intervals). Before treatment and at days 1, 3, 7, and 14 after treatment rats underwent DW-MRI and [

results5-FU inhibited the growth of CC531 tumors in a dose-dependent manner. Immunohistochemical analysis did not show significant changes in Ki67, TK1, and ENT1 expression. However, [

conclusionThis study suggests that 5-FU treatment induces a flare in [

Indexed as

Diffusion Magnetic Resonance ImagingPositron-Emission TomographyAnimalsCell DeathCell Line, TumorCell ProliferationColorectal NeoplasmsDideoxynucleosidesDisease Models, AnimalFluorouracilImmunohistochemistryLiver NeoplasmsRatsTomography, Emission-Computed, Single-PhotonTomography, X-Ray ComputedTreatment OutcomealovudineDideoxynucleosidesFluorouracil[18F]FLT PET5-FluorouracilColorectal cancerDiffusion-weighted MRIResponse monitoring

Identifiers

PMID27798786
PMCPMC5498638
OpenAlexW2539463029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.